UA80859C2 - Ganglioside based vaccine composition for subcutaneous administration without the use of adjuvants - Google Patents

Ganglioside based vaccine composition for subcutaneous administration without the use of adjuvants

Info

Publication number
UA80859C2
UA80859C2 UAA200508381A UA2005008381A UA80859C2 UA 80859 C2 UA80859 C2 UA 80859C2 UA A200508381 A UAA200508381 A UA A200508381A UA 2005008381 A UA2005008381 A UA 2005008381A UA 80859 C2 UA80859 C2 UA 80859C2
Authority
UA
Ukraine
Prior art keywords
adjuvants
subcutaneous administration
vssp
ganglioside
vaccine composition
Prior art date
Application number
UAA200508381A
Other languages
English (en)
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Publication of UA80859C2 publication Critical patent/UA80859C2/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001169Tumor associated carbohydrates
    • A61K39/001171Gangliosides, e.g. GM2, GD2 or GD3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
UAA200508381A 2003-02-27 2004-02-27 Ganglioside based vaccine composition for subcutaneous administration without the use of adjuvants UA80859C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20030047A CU23257A1 (es) 2003-02-27 2003-02-27 COMPOSICIONES VACUNALES A BASE DE GANGLIOSIDOS PARA LA ADMINISTRACION SUBCUTáNEA
PCT/CU2004/000003 WO2004075811A2 (es) 2003-02-27 2004-02-27 Composiciones vacunales a base de gangliósidos para administración subcutánea

Publications (1)

Publication Number Publication Date
UA80859C2 true UA80859C2 (en) 2007-11-12

Family

ID=40091613

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200508381A UA80859C2 (en) 2003-02-27 2004-02-27 Ganglioside based vaccine composition for subcutaneous administration without the use of adjuvants

Country Status (37)

Country Link
US (1) US8591917B2 (xx)
EP (1) EP1604683B1 (xx)
JP (1) JP4729475B2 (xx)
KR (1) KR100703570B1 (xx)
CN (1) CN100418576C (xx)
AR (1) AR043377A1 (xx)
AT (1) ATE353668T1 (xx)
AU (1) AU2004216554B2 (xx)
BR (1) BRPI0407854B1 (xx)
CA (1) CA2535214C (xx)
CL (1) CL2004000374A1 (xx)
CR (1) CR7965A (xx)
CU (1) CU23257A1 (xx)
CY (1) CY1106668T1 (xx)
DE (1) DE602004004768T2 (xx)
DK (1) DK1604683T3 (xx)
EA (1) EA008905B1 (xx)
EC (1) ECSP055978A (xx)
EG (1) EG26446A (xx)
ES (1) ES2280948T3 (xx)
GE (1) GEP20074120B (xx)
HK (1) HK1087630A1 (xx)
HR (1) HRP20050763A2 (xx)
IL (1) IL170355A (xx)
LT (1) LT5351B (xx)
LV (1) LV13400B (xx)
MY (1) MY139811A (xx)
NZ (1) NZ541952A (xx)
PE (1) PE20040955A1 (xx)
PT (1) PT1604683E (xx)
RS (1) RS20050664A (xx)
SI (1) SI1604683T1 (xx)
TN (1) TNSN05209A1 (xx)
TW (1) TWI344372B (xx)
UA (1) UA80859C2 (xx)
UY (1) UY28207A1 (xx)
WO (1) WO2004075811A2 (xx)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24534B1 (es) * 2017-11-06 2021-07-02 Ct Inmunologia Molecular Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3
CU20170173A7 (es) 2017-12-27 2019-11-04 Ct Inmunologia Molecular Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965198A (en) 1985-12-24 1990-10-23 Konica Corporation Monoclonal antibody and method of manufacturing hybridoma producing the same
US6149921A (en) * 1993-12-29 2000-11-21 Centro De Inmunologia Molecular Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment
CU22420A1 (es) * 1993-12-29 1996-01-31 Centro Inmunologia Molecular Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer
PE20020572A1 (es) * 2000-12-06 2002-07-31 Centro Inmunologia Molecular Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos
EP1293212A1 (en) * 2001-08-21 2003-03-19 National Research Council Of Canada Anti cancer vaccine comprising whole cancer cells with modified sialic acid

Also Published As

Publication number Publication date
BRPI0407854A (pt) 2006-02-14
WO2004075811A3 (es) 2004-10-14
BRPI0407854B1 (pt) 2019-02-26
CR7965A (es) 2008-10-29
EG26446A (en) 2013-11-07
NZ541952A (en) 2008-06-30
AU2004216554B2 (en) 2010-05-20
CN100418576C (zh) 2008-09-17
WO2004075811A2 (es) 2004-09-10
US8591917B2 (en) 2013-11-26
PE20040955A1 (es) 2005-02-03
DE602004004768D1 (de) 2007-03-29
EP1604683A2 (en) 2005-12-14
PT1604683E (pt) 2007-05-31
US20070148181A1 (en) 2007-06-28
TWI344372B (en) 2011-07-01
EA008905B1 (ru) 2007-08-31
RS20050664A (xx) 2007-11-15
CA2535214A1 (en) 2004-09-10
MY139811A (en) 2009-10-30
CU23257A1 (es) 2008-01-24
EA200501367A1 (ru) 2006-02-24
CN1753691A (zh) 2006-03-29
UY28207A1 (es) 2004-09-30
HK1087630A1 (en) 2006-10-20
DK1604683T3 (da) 2007-06-11
DE602004004768T2 (de) 2007-10-11
HRP20050763A2 (en) 2006-06-30
KR100703570B1 (ko) 2007-04-09
AR043377A1 (es) 2005-07-27
SI1604683T1 (sl) 2007-08-31
ECSP055978A (es) 2006-01-16
LV13400B (en) 2006-05-20
CA2535214C (en) 2012-01-10
JP4729475B2 (ja) 2011-07-20
AU2004216554A1 (en) 2004-09-10
CL2004000374A1 (es) 2005-05-06
LT5351B (lt) 2006-07-25
EP1604683B1 (en) 2007-02-14
CY1106668T1 (el) 2012-05-23
ATE353668T1 (de) 2007-03-15
LT2005087A (en) 2006-04-25
TNSN05209A1 (en) 2007-06-11
GEP20074120B (en) 2007-05-25
IL170355A (en) 2010-05-31
JP2006519186A (ja) 2006-08-24
ES2280948T3 (es) 2007-09-16
KR20060003857A (ko) 2006-01-11

Similar Documents

Publication Publication Date Title
RU2378009C2 (ru) Иммунизация против менингококков серогруппы y с помощью белков
MX2009008928A (es) Composiciones que comprenden conjugados de polisacaridos y su uso como vacunas.
PH12018501517A1 (en) Neisseria meningitidis compositions and methods thereof
WO2011156774A3 (en) Multivalent glycopeptide constructs and uses thereof
MX340096B (es) Formulaciones de vacuna meningococica.
FR13C0040I2 (fr) Vaccins polypeptidiques offrant une large protection contre des lignees de meningocoques hypervirulentes
MX2009001412A (es) Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas.
NO20064781L (no) Fremgangsmater og adjuvanser for a forbedre immunresponser mot vaksiner og fremgangsmater for anvendelse
UA99659C2 (uk) Мультивалентна вакцина з нативних везикул зовнішньої мембрани менінгококів, способи її застосування
PT1187629E (pt) Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
NO20082706L (no) Vaksine
JP2007533729A5 (xx)
NZ601538A (en) Vaccine compositions comprising a mutated factor h binding protein
WO2009060281A3 (en) Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties
DK2054431T3 (da) Konformere af bakterielle adhæsiner
DK1883387T3 (da) Beholder til flydende medikamenter, der skal administreres
CA2646574A1 (en) Vaccine against mycoplasma and prrsv
LT2005087A (en) Subcutaneously-administered ganglioside-based vaccine compositions
WO2010039924A3 (en) Th1 vaccination priming for active immunotheraphy
BRPI0410761A (pt) uso de leucina, e, composição para administração entérica a pacientes
MX2015013401A (es) Procedimiento de tratamiento.
RU2008144180A (ru) Вакцина против микоплазмы и prrsv
BR112013010338A2 (pt) composição, métodos para preparar uma composição imunogênica, para adjuvantar uma resposta imune, para eliciar uma resposta imune contra um agente infeccioso, para evitar e/ou reduzir a deposição de amilóide ou doença de alzheimer em um indivíduo, e para tratar/reduzir/melhorar a infecção por uma agente infeccioso, uso de uma proteína, e, kit
WO2005023295A3 (en) Naturally processed immunodominant peptides derived from neisseria meningitidis porin a protein and their use
MD2975G2 (ro) Remediu sub formă de gel pentru tratamentul rozaceei